DelveInsight’s, “Primary biliary cirrhosis Pipeline Insight, 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Primary biliary cirrhosis pipeline landscape. It covers the Primary Biliary Cirrhosis pipeline drug profiles, including Primary Biliary Cirrhosis clinical trials and nonclinical stage products. It also covers the Primary Biliary Cirrhosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Primary Biliary Cirrhosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Primary Biliary Cirrhosis clinical trials studies, Primary Biliary Cirrhosis NDA approvals (if any), and product development activities comprising the technology, Primary biliary cirrhosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Primary Biliary Cirrhosis Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Primary Biliary Cirrhosis pipeline landscape @ Primary Biliary Cirrhosis Pipeline Outlook Report
Primary Biliary Cirrhosis Overview
Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at time of diagnosis, and 90% are women. Annual incidence is estimated between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population (depending on age and sex). PBC does not always cause symptoms, but some people may experience: bone and joint aches, fatigue (extreme tiredness), itchy skin, dry eyes and mouth, pain or discomfort in the upper right side of their tummy.
Latest Developmental Activities in the Primary Biliary Cirrhosis Treatment Landscape
Find out more about the Primary Biliary Cirrhosis Diagnosis and Treatment of patients @ Primary Biliary Cirrhosis Ongoing Clinical Trials Analysis
Primary Biliary Cirrhosis Emerging Drugs Profile
Elafibranor: Genfit
Elafibranor is an investigational compound. GENFIT is currently evaluating its proprietary drug candidate, elafibranor, a dual agonist of PPARα and PPARδ in PBC. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory activity. The use of drugs targeting PPAR receptors has been shown to reduce blood levels of Alkaline Phosphatase (ALP), and improve biochemical measures of cholestasis and pruritus (itching) in patients with PBC.
Seladelpar: CymaBay Therapeutics
Seladelpar (MBX-8025) is a potent, selective, orally active peroxisome proliferator-activated receptor δ (PPARδ) agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). It has received Breakthrough Therapy Designation (FDA) and PRIME status (EMEA); Orphan Drug Designation in U.S. and Europe. Backed by an extensive body of clinical evidence and global patient experience through its Phase 2 and Phase 3 (ENHANCE) studies of seladelpar in Primary Biliary Cholangitis (PBC), CymaBay initiated an international pivotal Phase 3 study (RESPONSE) in early 2021.
Setanaxib: Calliditas Therapeutics
Calliditas’ pipeline contains development programs based on a first in class, novel NOX inhibitor platform that includes lead compound setanaxib, the first NOX inhibitor to reach the clinical trial stage. NOX enzyme inhibitors are a set of promising novel experimental drugs in a new therapeutic class, recognised by the WHO since 2019 when it approved “naxib” as a new stem. Calliditas launched trials with setanaxib in Primary Biliary Cholangitis (PBC) and in Squamous Cell Carcinoma of the Head & Neck (SCCHN).
Primary Biliary Cirrhosis Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Primary biliary cirrhosis. The companies which have their Primary biliary cirrhosis drug candidates in the most advanced stage, i.e. phase III include, Genfit.
Discover more about the list of Primary Biliary Cirrhosis FDA-approved drugs for Primary Biliary Cirrhosis @ Primary Biliary Cirrhosis Treatment Landscape
Scope of the Primary Biliary Cirrhosis Pipeline Report
Dive deep into rich insights for Primary Biliary Cirrhosis Emerging Therapies and Ongoing Clinical Trials; visit @ Primary Biliary Cirrhosis Emerging Therapies and Key Players
Table of Content
For further information on the Primary Biliary Cirrhosis Pipeline therapeutics, reach out to Primary Biliary Cirrhosis Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services